The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study to compare docetaxel plus S-1 with cisplatin plus S-1 in advanced gastric cancer without measurable lesions (HERBIS-3).
 
Yukinori Kurokawa
Honoraria - Chugai Pharma; Lilly Japan; Novartis; Taiho Pharmaceutical; Yakult Honsha
Updated Results of Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin's Disease Using Cyclophosphamide Platinum and BCNU (CPB/STAMP I).
 
Jin Matsuyama
No Relationships to Disclose
 
Kazuhiro Nishikawa
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical; Yakult Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yutaka Kimura
No Relationships to Disclose
 
Atsushi Takeno
No Relationships to Disclose
 
Junji Kawada
No Relationships to Disclose
 
Ryohei Kawabata
No Relationships to Disclose
 
Youichi Makari
No Relationships to Disclose
 
Shigeyuki Tamura
No Relationships to Disclose
 
Yuichiro Doki
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
 
Daisuke Sakai
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Toshio Shimokawa
No Relationships to Disclose
 
Taroh Satoh
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)